-
公开(公告)号：US20230416674A1
公开(公告)日：2023-12-28
申请号：US18459381
申请日：2023-08-31
Applicant: Pfizer Inc.
Inventor： Bruno FIGUEROA , Yen-Tung Luan , Wenge Wang
CPC classification number: C12N5/0018 , C12N5/0682 , C12N2511/00 , C12N2500/32 , C12N2500/50
Abstract: A cell culture medium comprising tyrosine at a concentration of at least 3 mM and polyvinylalcohol (PVA).
-
公开(公告)号：US20190030183A1
公开(公告)日：2019-01-31
申请号：US15748268
申请日：2016-08-09
Applicant: PFIZER INC.
Inventor： Xiaotian Zhong , Amarnauth Shastrie Prashad , Ronald William Kriz , Tao He , Will Somers , Wenge Wang , Leo Joseph Letendre
Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
-
Patent Agency Ranking
公开(公告)号：US20140322758A1
公开(公告)日：2014-10-30
申请号：US14352740
申请日：2012-10-09
Applicant: Pfizer Inc.
Inventor： Wenge Wang , Yen-Tung Luan , Denis Drapeau
CPC classification number: C12N5/0018 , C12N5/0682 , C12N2500/24 , C12N2511/00 , C12P21/00
Abstract: The present invention provides, among other things methods of increasing cell density, viability and/or titer in a cell culture including steps of adding a composition comprising iron to the cell culture.
Abstract translation: 本发明尤其提供了增加细胞培养物中的细胞密度，活力和/或滴度的方法，包括向细胞培养物中加入包含铁的组合物的步骤。
-
公开(公告)号：US10653794B2
公开(公告)日：2020-05-19
申请号：US15748268
申请日：2016-08-09
Applicant: PFIZER INC.
Inventor： Xiaotian Zhong , Amarnauth Shastrie Prashad , Ronald William Kriz , Tao He , Will Somers , Wenge Wang , Leo Joseph Letendre
Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
-
公开(公告)号：US20190112572A1
公开(公告)日：2019-04-18
申请号：US16088676
申请日：2017-03-23
Applicant: Pfizer Inc.
Inventor： Bruno FIGUEROA , Yen-Tung Luan , Wenge Wang
Abstract: A cell culture medium comprising tyrosine at a concentration of at least 3 mM and polyvinylalcohol (PVA).
-
公开(公告)号：US20200230256A1
公开(公告)日：2020-07-23
申请号：US16807375
申请日：2020-03-03
Applicant: PFIZER INC.
Inventor： Xiaotian Zhong , Amarnauth Shastrie Prashad , Ronald William Kriz , Tao He , Will Somers , Wenge Wang , Leo Joseph Letendre
Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
-
公开(公告)号：US11980669B2
公开(公告)日：2024-05-14
申请号：US16807375
申请日：2020-03-03
Applicant: PFIZER INC.
Inventor： Xiaotian Zhong , Amarnauth Shastrie Prashad , Ronald William Kriz , Tao He , Will Somers , Wenge Wang , Leo Joseph Letendre
CPC classification number: A61K47/6889 , A61K38/05 , A61K47/68 , A61K47/6817 , A61K47/6851 , A61K47/6855 , C07K16/00 , C07K16/30 , C07K2317/14 , C07K2317/40 , C07K2317/526 , C07K2317/55 , C07K2317/94
Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
-
-
-
-
-
-
Search Results
7
records
(took 0.027 seconds)
